Rodenhuis S
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Oncologist. 2000;5(5):369-75. doi: 10.1634/theoncologist.5-5-369.
High-dose chemotherapy in breast cancer is a subject of considerable controversy. Preliminary results from several randomized trials have shown that it is certainly not the breakthrough hoped for in the early 1990s. The available data are, however, compatible with a modest but potentially important effect on relapse-free survival in the adjuvant treatment of high-risk breast cancer. To prove such an effect, several more years of maturation are required for a number of randomized studies. At this point in time, there is no justification for the use of high-dose chemotherapy in breast cancer outside clinical studies.
乳腺癌的大剂量化疗是一个颇具争议的话题。几项随机试验的初步结果表明，它肯定不是20世纪90年代初所期望的突破。然而，现有数据与大剂量化疗在高危乳腺癌辅助治疗中对无复发生存率有适度但潜在重要影响的观点相符。为了证实这种效果，一些随机研究还需要数年时间才能成熟。目前，在临床研究之外，没有理由在乳腺癌治疗中使用大剂量化疗。
